The BBB is formed by the brain capillary endothelium and excludes from the brain ~100% of large-molecule therapeutics and more than 98% of all small-molecule drugs. Overcoming the difficulty of deliverying therapeutic agents to specific regions of the brain presents a major challenge to treatment of most brain disorders. In its neuroprotective role, the blood-brain barrier functions to hinder the delivery of many potentially important diagnostic and therapeutic agents to the brain. Therapeutic molecules and antibodies that might otherwise be effective in diagnosis and therapy do not cross the BBB in adequate amounts.
Our devices are designed to achieve:
Alternative technologies used to deliver therapeutics to the brain have limited success. Intracavitary delivery methods rely on the inefficient kinetics of diffusion. Other catheter-based technologies provide only small volume delivery solutions.
- Better Drug Distribution
- Therapeutics are delivered utilizing hydrostatic pressure, to a specific location and over a defined period of time, resulting in a larger and more predictable distribution profile than other approaches
- Avoidence of Systemic Side Effects
- Therapeutic delivery targets a precisely defined area within the brain, thereby avoiding systemic side effects.
- Minimization of Backflow
- Proprietary anti-backflow features allow the drug to enter the treatment area, as opposed to refluxing around the catheter.
59 year old male diagnosed with a glioblastoma in 2015. He underwent a surgical resection followed by radiation and temozolomide chemotherapy and had a recurrent tumor seven months later. He then underwent a second surgical resection followed by etoposide chemotherapy. Four months later he developed another recurrent tumor and enrolled in the infuseon pilot study.
Pilot Study: Topotecan Infusion Summary:
- Infusion Duration: 72 hours
- # CMCs: 2
- Volume of distribution: 72 cc
- Volume of infusion: 40 cc